



Cell4Cure Builds Strategic Connections at Swiss Nordic Bio 2026

Solna, Stockholm Region, Sweden – October 5, 2026 – Cell4Cure participated in Swiss Nordic Bio 2026 in Zurich on October 1, meeting with investors and potential strategic partners to discuss its proprietary immune tolerance platform and explore opportunities for investment and co-development.

Swiss Nordic Bio brought together biotech and pharmaceutical companies, investors and other stakeholders from across the Swiss and Nordic life science ecosystems, providing a valuable setting for networking and discussions around innovative life science technologies.

Representing Cell4Cure was Co-founder and Business Development Lead Fredrik Gustavsson, who discussed the company's antigen-specific immune tolerance platform based on tolerogenic dendritic cells, with an initial proof-of-concept program focused on Fabry disease. The program aims to prevent the formation of anti-drug antibodies (ADAs) in patients receiving enzyme replacement therapy.

The conference provided an opportunity to discuss Cell4Cure's technology and development program with new contacts and explore potential investment and co-development opportunities.

Following the event, Cell4Cure looks forward to continuing the discussions initiated in Zurich and exploring collaborations with investors and strategic partners as the company advances its Fabry disease program towards clinical development.

For more information, please contact:

Christina Herder, CEO

Telephone: +46703747156

Email: christina.herder@cell4cure.com

About Cell4Cure

Founded in 2023, Cell4Cure AB is a Swedish biotech company pioneering immune tolerance therapies to address critical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company's proprietary platform is based on ex vivo-engineered dendritic cells (DCs) designed to induce antigen-specific immune tolerance while preserving essential immune function. Backed by \$30 million in research and development investments, Cell4Cure has achieved key milestones, including European Medicines Agency (EMA) approval for clinical trials and the establishment of robust GMP manufacturing processes.

Cell4Cure AB | Org nr: 559445-7979

Gustav III:s Boulevard, 16972 Solna, Sweden

Website: www.cell4cure.com

[Cell4Cure](#) | [LinkedIn](#)